NewsBenzingaNovo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To... Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To... Benzinga 2026.09.29 10:35 (GMT+0) Open on Benzinga Other news Kimberly-Clark's Dividend And Safe Haven Trade Outweigh Post-Merger Risks (NASDAQ:KMB) Netlist Opens New Legal Proceedings At U.S. International Trade Commission Seeking Exclusion And Cease And Desist Orders Against Micron Technology And MU's Customers Nvidia, Broadcom And Google; Claims Infringement Of The Company's HBM Patents Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6 This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Why Tesla Stock Is Still Not a Buy Johnson & Johnson To Present New Findings On IMAAVY For Treatment Of Generalized Myasthenia Gravis Across 15 Novel Abstracts At 2026 MGFA Scientific Session And AANEM Annual Meeting
Netlist Opens New Legal Proceedings At U.S. International Trade Commission Seeking Exclusion And Cease And Desist Orders Against Micron Technology And MU's Customers Nvidia, Broadcom And Google; Claims Infringement Of The Company's HBM Patents
Johnson & Johnson To Present New Findings On IMAAVY For Treatment Of Generalized Myasthenia Gravis Across 15 Novel Abstracts At 2026 MGFA Scientific Session And AANEM Annual Meeting
